bioAffinity Technologies, Inc. (NASDAQ:BIAF) Sees Significant Decrease in Short Interest

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the target of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 396,800 shares, a decline of 7.2% from the January 15th total of 427,500 shares. Currently, 4.2% of the shares of the company are short sold. Based on an average daily volume of 172,600 shares, the short-interest ratio is currently 2.3 days.

Institutional Trading of bioAffinity Technologies

A hedge fund recently raised its stake in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC raised its holdings in bioAffinity Technologies, Inc. (NASDAQ:BIAF) by 131.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 46,304 shares of the company’s stock after buying an additional 26,304 shares during the quarter. Sheaff Brock Investment Advisors LLC owned 0.30% of bioAffinity Technologies worth $42,000 as of its most recent SEC filing. 1.64% of the stock is currently owned by hedge funds and other institutional investors.

bioAffinity Technologies Price Performance

NASDAQ BIAF opened at $0.81 on Tuesday. The stock has a 50-day simple moving average of $0.85 and a 200 day simple moving average of $1.33. The stock has a market capitalization of $12.63 million, a PE ratio of -0.99 and a beta of 2.95. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.01 and a current ratio of 1.02. bioAffinity Technologies has a twelve month low of $0.57 and a twelve month high of $3.62.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.